CSV November 7, 2022 through November 7, 2024 All Errata for USP–NF How to use

×

**How to Use**

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ISOSORBIDE | *Assay* | *USP41–NF36* | 2272 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second* | Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| DINITRATE SUBLINGUAL TABLETS | | | | | | | *Supplement to USP41–NF36* | *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter.<br>AND<br>Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | chromatograms, and measure the responses for the major peaks. |
| REAGENTS | SOLUTIONS/*Volumetric Solutions* | *USP41–NF36* | 5769 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *0.1 N Potassium Hydroxide VS*: Change Transfer 100 mL of potassium hydroxide to a 1000-mL volumetric flask. to: Transfer 100 mL of *1 N Potassium Hydroxide VS* to a 1000-mL volumetric flask. |
| REPOSITORY CORTICOTROPIN INJECTIONS | ADDITIONAL REQUIREMENTS | *USP41–NF36* | 1097 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In *USP Reference Standards <11>*: Add USP Ascorbic Acid RS |
| ISOSORBIDE DINITRATE CHEWABLE | *Assay* | *USP41–NF36* | 2270 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Change *Buffer solution, Mobile phase,* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| TABLETS | | | | | | | | *Internal standard solution, Standard preparation,* and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>.) *Internal standard solution* —Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter.<br>AND<br>Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | the responses for the major peaks. |
| REAGENTS | REAGENT SPECIFICATIONS | *USP41–NF36* | 5680 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *Carbon Disulfide, CS*: Change Carbon Disulfide, CS to: Carbon Disulfide, $CS_2$ |
| COLCHICINE | IMPURITIES/*Limit of Ethyl Acetate*/*System suitability*/*Suitability requirements* | *First Supplement to USP41–NF36* | 8314 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Delete *Tailing factor*: NMT 2.0 for the menthol peak |
| ARGATROBAN | IMPURITIES/*Organic Impurities* | *USP41–NF36* | 346 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Footnote b of *Table 2*: Change Ethyl (2*R*,4*R*)-1-[$N^8$-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate hydrochloride. to: Ethyl (4*R*)-1-[$N^8$-nitro- |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | L-arginyl]-4-methylpiperidine-2-carboxylate. |
| ISOSORBIDE DINITRATE TABLETS | *Assay* | *USP41–NF36* | 2270 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | mix to obtain a solution having a pH of about 4.7.<br>*Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>).<br>*Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter.<br>AND<br>Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 220-nm detector and a |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. |
| ZONISAMIDE CAPSULES | PERFORMANCE TESTS/ *Dissolution <711>* | *USP41–NF36* | 4410 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *Apparatus 2*: Change 75 rpm, with sinkers (see *Dissolution* <711>, *Figure 2a*) to: 75 rpm. Use suitable sinkers, if necessary. |
| REAGENTS/INDICATORS AND SOLUTIONS | SOLUTIONS/*Volumetric Solutions*/*0.01 M Sodium Thiosulfate VS* | *USP41–NF36* | 5772 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In the equation in *Standardization*: Change N = mg $K_2Cr_2O_7$/49.04 x mL $Na_2S_2O_3$ to: M = mg K |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | $^{2}Cr_2O_7$/49.04 x mL $Na_2S_2O_3$ |
| DESLORATADINE TABLETS | IMPURITIES | *USP41–NF36* | 1178 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | *Organic Impurities*: Add Protect all solutions containing desloratadine from light. |
| ISOSORBIDE DINITRATE SUBLINGUAL TABLETS | *Identification* | *USP41–NF36* | 2272 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1: Change Tablets respond to the *Identification* test under *Isosorbide Dinitrate Tablets*. to: Transfer a suitable quantity of finely powdered Tablets to a glass-stoppered centrifuge tube. Add 10 mL of sodium hydroxide solution (1 in 250), shake to wet the powder, |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | then add 15 mL of solvent hexane, and again shake. Centrifuge the mixture, and transfer the upper phase to a beaker. Evaporate the solvent, and dry the residue in vacuum over anhydrous calcium chloride at room temperature for 16 hours: the IR absorption spectrum of a suitable solution in chloroform of the residue so obtained exhibits maxima only at the same wavelengths as that of a similar preparation from the residue |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | obtained from USP Diluted Isosorbide Dinitrate RS. |
| HYDROGENATED VEGETABLE OIL | DEFINITION | *USP41–NF36* | 5649 | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 2: Change The melting range, heavy metals limit, iodine value, and saponification value differ, to: The melting range, iodine value, and saponification value differ, |
| PEMETREXED FOR INJECTION | ASSAY/ *Procedure/Analysis* | *First Supplement to USP41–NF36* | Online | 27-Apr-2018 | 1-May-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 8 of the variable definition list: Change $M_{r2}$ = molecular weight of pemetrexed disodium (anhydrous), 473.37 to: $M_{r2}$ = molecular weight of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | pemetrexed disodium (anhydrous), 471.38 |
| SALMETEROL INHALATION POWDER | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP40–NF35* | 6096 | 30-Mar-2018 | 1-Apr-2018 | *USP42–NF37* | *USP42–NF37* | Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76 |
| FLUTICASONE PROPIONATE | ADDITIONAL REQUIREMENT | *USP40–NF35* | 4309 | 30-Mar-2018 | 1-Apr-2018 | *USP42–NF37* | *USP42–NF37* | Line 2 of USP Salmeterol |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| AND SALMETEROL INHALATION POWDER | S/*USP Reference Standards <11>* | | | | | | | Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76 |
| PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/*Tin in Non-Tin-Stabilized Materials* | *USP41–NF36* | 6403 | 30-Mar-2018 | 1-Apr-2018 | *USP42–NF37* | *USP42–NF37* | Line 3 of *Sample solution*: Change If the solution is not colorless, add the sodium sulfate |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to:<br>If the solution is not colorless, add the sodium sulfite |
| PERINDOPRIL ERBUMINE | IM PURITIES/*Limit of Perindopril Related Compound I*/*System suitability* | *USP40–NF35* | 5644 | 30-Mar-2018 | 1-Apr-2018 | *USP42–NF37* | *USP42–NF37* | Line 3: Add [Note—The relative retention times for perindopril and perindopril related compound I are 1.0 and 1.6, respectively.] |
| CHLORHEXIDINE GLUCONATE ORAL RINSE | *Identification* | *USP40–NF35* | 3367 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *C*: Change Undiluted Oral Rinse used as the test solution meets the requirements for *Identification* test *B* under *Calcium Gluconate*, except that a Standard solution containing about 0.6 mg of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | USP Potassium Gluconate RS per mL is used and 15 ?L of the test solution and the Standard solution are applied to the thin-layer chromatographic plate.<br>to:<br>Use undiluted Oral Rinse as the test solution and prepare a Standard solution of USP Potassium Gluconate RS in water containing 0.6 mg/mL. Apply separate 15-?L portions of the test solution and the Standard solution to a suitable thin- |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | layer chromatographic plate (see *Chromatography* <621>) coated with a 0.25-mm layer of chromatographic silica gel, and allow to dry. Develop the chromatogram in a solvent system consisting of a mixture of alcohol, water, ammonium hydroxide, and ethyl acetate (50:30:10:10) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the chamber, and dry at 110° for 20 minutes. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Allow to cool and spray with a spray reagent prepared as follows. Dissolve 2.5 g of ammonium molybdate in about 50 mL of 2 N sulfuric acid in a 100-mL volumetric flask, add 1.0 g of ceric sulfate, swirl to dissolve, dilute with 2 N sulfuric acid to volume, and mix. Heat the plate at 110° for about 10 minutes: the principal spot obtained from the test solution corresponds in color, size, and $R_F$ value to that obtained from the Standard solution. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| REAGENTS | REAGENT SPECIFICATIONS | *USP41–NF36* | 5724 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 2 of *9Z-Retinoic Acid*: Change *Acidalitretinoin)*, to: *Alitretinoin)*, |
| AMLODIPINE AND ATORVASTATIN TABLETS | IMPURITIES/*Organic Impurities Related to Atorvastatin* | *First Supplement to USP41–NF36* | 8270 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In the variable definition list in *Analysis*: Change $M_{r2}$ = molecular weight of atorvastatin calcium, 1209.39 to: $M_{r2}$ = molecular weight of atorvastatin calcium, 1155.34 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | IMPURITIES/*Organic Impurities, Procedure 2*/*Table 3* | *USP40–NF35* | 5728 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Footnote m: Change (2*S*,5*R*,6*R*)-Ethyl 6-((*R*)-2-{(2*S*,5*R*,6*R*)-6-[(*R*)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | )-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamido}-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate.<br>to:<br>2-(((3-Acetyl-4-(ethoxycarbonyl)-5,5-dimethylthiazolidin-2-yl)methyl)amino)-2-oxo-1-phenylethyl 6-(2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. |
| AMLODIPINE AND ATORVASTATIN | ASSAY/ *Procedure* | *First Supplement to USP41–NF36* | 8270 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In the variable definition list of the second |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| TABLETS | | | | | | | | equation in *Analysis*:<br>Change<br>$M_{r2}$ = molecular weight of atorvastatin calcium, 1209.39<br>to:<br>$M_{r2}$ = molecular weight of atorvastatin calcium, 1155.34 |
| NOREPINEPHRINE BITARTRATE | IDENTIFICATION/*B. Procedure* | *USP40–NF35* | 5380 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *Analysis*:<br>Change<br>Add 1 drop of ferric chloride TS.<br>to:<br>Add 1 drop of ferric chloride TS to 2 mL of *Sample solution*. |
| INHALATION AND NASAL DRUG PRODUCTS: AEROSOLS, | C. AERODYNAMIC SIZE DISTRIBUTION—INHALATION AEROSOLS, | *USP41–NF36* | 6327 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | *Figure 6*:<br>Change<br>Boquilla del Inhalador<br>to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| SPRAYS, AND POWDERS—PERFORMANCE QUALITY TESTS | SPRAYS, AND POWDERS | | | | | | | Inhaler Mouthpiece AND Change Tubo de Admisión to: Induction Port AND Change Cono de Ingreso to: Entrance Cone |
| ANTIBIOTICS—MICROBIAL ASSAYS | CALCULATIONS/*Turbidimetric Assay*/*Sample Data* | *USP40–NF35* | 143 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Second equation in *Step 1*: Change 0.0125 = to: 0.0062 = AND Third equation in *Step 1*: Change 0.0325 = to: 0.0322 = |
| PAROXETINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/*USP Reference* | *First Supplement to USP40–NF35* | Online | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of USP Paroxetine Related Compound F |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Standards <11>* | | | | | | | RS: Change *trans* (?)-1-Methyl-3-[1,3-benzodioxol-5-yloxy)methyl]-4-(fluorophenyl)piperidine. to: (3*S*,4*R*)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine. |
| AMLODIPINE AND ATORVASTATIN TABLETS | PERFORMANCE TESTS/ *Dissolution <711>* | *First Supplement to USP41–NF36* | 8270 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In the variable definition list of the second equation in *Analysis*: Change $M_{r2}$ = molecular weight of atorvastatin calcium, 1209.39 to: $M_{r2}$ = molecular weight of atorvastatin calcium, 1155.34 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE | ASSAY/ *Procedure* | *USP40–NF35* | 5380 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *Sample solution*: Change 25 mg/mL of Norepinephrine Bitartrate in glacial acetic acid. If necessary warm slightly to effect solution. to: Dissolve 500 mg of Norepinephrine Bitartrate in 20 mL of glacial acetic acid, warming slightly if necessary to effect solution. |
| STATISTICAL TOOLS FOR PROCEDURE VALIDATION | 3. ACCURACY AND PRECISION/*3.1 Methods for Estimating Accuracy and Precision* | *USP41–NF36* | 7622 | 23-Feb-2018 | 1-Mar-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Paragraph 4: Change For example, with ? = 0.05 and $n$ = 9, $t_{0.95:8}$ = 1.860 provides a 100(1? 2 × 1.05)% |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to:<br>For example, with ? = 0.05 and $n$ = 9, $t_{0.95:8}$ = 1.860 provides a 100(1 ? 2 × 0.05)% |
| POWDERED ECHINACEA PALLIDA EXTRACT | IDENTIFICATION | *USP40–NF35* | 6935 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, AND Lines 3 and 6 of *C*.: Change *Standard solution B,* to: *Standard solution C,* AND Change *Standard solution C*) to: *Standard solution D*) |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| PHENYTOIN ORAL SUSPENSION | PERFORMANCE TESTS/ *Dissolution <711>* | *USP41–NF36* | 3286 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | In the *Analysis*: Change $C_S$ = concentration of USP Phenytoin RS in the *Standard solution* to: $C_S$ = concentration of USP Phenytoin RS in the *Standard solution* (mg/mL) |
| ESZOPICLONE TABLETS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *Revision Bulletin (Official August 01, 2017)* | Online | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | $C_{17}H_{17}ClN_6O_4$ 404.81 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. |
| | | | | | | | | $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38 |
| POWDERED DIGITALIS | IDENTIFICATION/*B. Thin-Layer Chromatographic Identification Test* | *USP40–NF35* | 3762 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 3 of *Standard solution A*: Change lead acetate, to: lead acetate TS, AND Line 11 of *Analysis*: Change Locate the two prominent bands from *Standard solution A* corresponding in $R_F$ value to the two bands from *Standard solution B*. to: Locate the prominent bands from *Standard solution A* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | corresponding in $R_F$ value to the band from *Standard solution B*. |
| NEVIRAPINE TABLETS | IMPURITIES/*Organic Impurities* | *USP40–NF35* | 5333 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *Standard solution*: Change 0.125 ?g/mL of USP Nevirapine Anhydrous RS from *Standard stock solution A* in *Diluent* to: 0.125 ?g/mL of USP Nevirapine Anhydrous RS in *Diluent* |
| ECHINACEA PALLIDA | IDENTIFICATION | *USP40–NF35* | 6931 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System suitability*: Change *Standard* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated,<br>to:<br>*Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated,<br>AND<br>Lines 3 and 6 of *C.*: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *Standard solution B*, to: *Standard solution C*, AND Change *Standard solution C*) to: *Standard solution D*) |
| POWDERED ECHINACEA PURPUREA | IDENTIFICATION | *USP40–NF35* | 6942 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 3 of *A. Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacoside/System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, |
| ECHINACEA SPECIES POWDER CAPSULES | IDENTIFICATION | *USP41–NF36* | 4595 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 4 of *A. HPTLC for Articles of Botanical Origin <203>/For Capsules containing Echinacea angustifolia* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *powder prepared from dried rhizome and roots*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid (higher $R_F$) and chlorogenic acid |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | (lower $R_F$) that are clearly separated, |
| TIMOLOL MALEATE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *First Supplement to USP40–NF35* | 8416 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 2 of USP Timolol Related Compound A RS: Change (*R*)-1-(*tert*-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol. $C_{13}H_{24}N_4O_3S$ 316.42 to:<br><br>(*R*)-1-(*tert*-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate. $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$ 432.49 AND Line 2 of USP Timolol Related Compound C RS: Change *N*-(*tert* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | -Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine. $C_{19}H_{31}N_7O_4S_2$ 485.19 to: *N*-(*tert*-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate. $C_{19}H_{31}N_7O_4S_2$ ? $C_4H_4O_4$ 601.69 AND Line 3 of USP Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to: $C_6H_9N_3O_2S$ AND Line 2 of USP Timolol Related Compound E RS: Change (*S*)-3-(*tert*-Butylamino)-1-( |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | 4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-yl hydrogen maleate. $C_{17}H_{26}N_4O_6S$ 414.48 to: (*S*,*Z*)-4-({1-(*tert*-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl}oxy)-4-oxobut-2-enoic acid maleate salt (1:1) $C_{17}H_{26}N_4O_6S$ ? $C_4H_4O_4$ 530.55 |
| IMMUNOLOGICAL TEST METHODS—ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) / *Solid Phase* | PROCEDURES | *USP40–NF35* | 1344 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 7 of *Coating the Solid Phase—Immobilization of Capture Reagent*: Change 1–10 µg/well to: 1–10 µg/mL |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ESZOPICLONE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP40–NF35* | 4090 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazi |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | ne-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38 |
| POWDERED ECHINACEA ANGUSTIFOLIA | IDENTIFICATION | *USP40–NF35* | 6926 | | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and dicaffeoylquinic acid*/*System suitability*: Change *Standard solution B* shows two |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, AND Line 3 of *C*.: Change *Standard solution B*, |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ECHINACEA PURPUREA AERIAL PARTS | IDENTIFICATION | *USP40–NF35* | 6937 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | to: *Standard solution C*, Line 3 of *A. Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacoside/System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) that are clearly separated, to: *Standard solution B* shows two |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ECHINACEA SPECIES DRY EXTRACT CAPSULES | IDENTIFICATION | *USP41–NF36* | 4590 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, Line 4 of *A. HPTLC for Articles of Botanical Origin <203>*/*For Capsules containing Echinacea angustifolia Dry Extract*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, |
| QUETIAPINE EXTENDED-RELEASE TABLETS | IMPURITIES/*Organic Impurities* | *Revision Bulletin (Official November 01, 2017)* | Online | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Footnote a of *Table 5*: Change total impurities. to: total degradation products. AND Footnote b: Change total impurities. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to: total degradation products. |
| DOBUTAMINE IN DEXTROSE INJECTION | *Identification* | *USP40–NF35* | 3843 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 1 of *B*: Change It meets the requirements for the *Identification* test under *Dextrose*. to: Add a few drops of a solution (1 in 20) to 5 mL of hot alkaline cupric tartrate TS. A copious red precipitate of cuprous oxide is formed. |
| TIMOLOL MALEATE TABLETS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP40–NF35* | 6481 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 3 of USP Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to: $C_6H_9N_3O_2S$ |
| POWDERED ECHINACEA | IDENTIFICATION | *USP40–NF35* | 6933 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to* | Line 5 of *A. Thin-Layer Chro* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| PALLIDA | | | | | | | *USP41–NF36* | *matography/Presence of echinacoside and absence of dicaffeoylquinic acid*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, AND Lines 3 and 6 of *C.*: Change *Standard solution B,* to: *Standard solution C,* AND Change *Standard solution C*) to: *Standard solution D*) |
| POWDERED ECHINACEA PURPUREA EXTRACT | IDENTIFICATION | *USP40–NF35* | 6944 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second Supplement to USP41–NF36* | Line 3 of *A. Thin-Layer Chromatography/Presence of chicoric acid and absence of echinacoside/System suitability*: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| BRETYLIUM | *Identification* | *USP40–NF35* | 3049 | 26-Jan-2018 | 1-Feb-2018 | *USP42–NF37* | *Second* | Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower $R_F$) and chlorogenic acid (higher $R_F$) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher $R_F$) and chlorogenic acid (lower $R_F$) that are clearly separated, Line 1 of *B*: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| TOSYLATE IN DEXTROSE INJECTION | | | | | | | *Supplement to USP41–NF36* | Change It responds to the *Identification test* under *Dextrose*. to: Add a few drops of a solution (1 in 20) to 5 mL of hot alkaline cupric tartrate TS. A copious red precipitate of cuprous oxide is formed. |

**Pagination**


- First page « First
- Previous page ‹ Previous
- …
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23